Chapter 1. Executive Summary
1.1. Market Snapshot
1.2. Global & Segmental Market Estimates & Forecasts, 2019-2027 (USD Billion)
1.2.1. Hospital acquired infections therapeutic Market, by region, 2019-2027 (USD Billion)
1.2.2. Hospital acquired infections therapeutic Market, by Infection Type, 2019-2027 (USD Billion)
1.2.3. Hospital acquired infections therapeutic Market, by Drug Class, 2019-2027 (USD Billion)
1.3. Key Trends
1.4. Estimation Methodology
1.5. Research Assumption
Chapter 2. Global Hospital acquired infections therapeutic Market Definition and Scope
2.1. Objective of the Study
2.2. Market Definition & Scope
2.2.1. Scope of the Study
2.2.2. Industry Evolution
2.3. Years Considered for the Study
2.4. Currency Conversion Rates
Chapter 3. Global Hospital acquired infections therapeutic Market Dynamics
3.1. Hospital acquired infections therapeutic Market Impact Analysis (2019-2027)
3.1.1. Market Drivers
3.1.1.1. Rise in approval and launch of new drugs
3.1.1.2. Increasing hospitalization due to rising burden of chronic diseases
3.1.2. Market Challenges
3.1.2.1. Declining demand for HAI drugs
3.1.3. Market Opportunities
3.1.3.1. High prevalence of HAIs
Chapter 4. Global Hospital acquired infections therapeutic Market Industry Analysis
4.1. Porter's 5 Force Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.1.6. Futuristic Approach to Porter's 5 Force Model (2018-2027)
4.2. PEST Analysis
4.2.1. Political
4.2.2. Economical
4.2.3. Social
4.2.4. Technological
4.3. Investment Adoption Model
4.4. Analyst Recommendation & Conclusion
Chapter 5. Global Hospital acquired infections therapeutic Market, by Infection Type
5.1. Market Snapshot
5.2. Global Hospital acquired infections therapeutic Market by Infection Type, Performance - Potential Analysis
5.3. Global Hospital acquired infections therapeutic Market Estimates & Forecasts by Infection Type 2018-2027 (USD Billion)
5.4. Hospital acquired infections therapeutic Market, Sub Segment Analysis
5.4.1. Urinary Tract Infections
5.4.2. Ventilator Associated Pneumonia
5.4.3. Surgical Site Infections
5.4.4. Bloodstream Infections
5.4.5. Others
Chapter 6. Global Hospital acquired infections therapeutic Market, by Drug Class
6.1. Market Snapshot
6.2. Global Hospital acquired infections therapeutic Market by Drug Class, Performance - Potential Analysis
6.3. Global Hospital acquired infections therapeutic Market Estimates & Forecasts by Drug Class 2018-2027 (USD Billion)
6.4. Hospital acquired infections therapeutic Market, Sub Segment Analysis
6.4.1. Antibacterial Drugs
6.4.2. Antiviral Drugs
6.4.3. Antifungal Drugs
Chapter 7. Global Hospital acquired infections therapeutic Market, Regional Analysis
7.1. Hospital acquired infections therapeutic Market, Regional Market Snapshot
7.2. North America Hospital acquired infections therapeutic Market
7.2.1. U.S. Hospital acquired infections therapeutic Market
7.2.1.1. Infection Type breakdown estimates & forecasts, 2018-2027
7.2.2. Canada Hospital acquired infections therapeutic Market
7.3. Europe Hospital acquired infections therapeutic Market Snapshot
7.3.1. U.K. Hospital acquired infections therapeutic Market
7.3.2. Germany Hospital acquired infections therapeutic Market
7.3.3. France Hospital acquired infections therapeutic Market
7.3.4. Spain Hospital acquired infections therapeutic Market
7.3.5. Italy Hospital acquired infections therapeutic Market
7.3.6. Rest of Europe Hospital acquired infections therapeutic Market
7.4. Asia-Pacific Hospital acquired infections therapeutic Market Snapshot
7.4.1. China Hospital acquired infections therapeutic Market
7.4.2. India Hospital acquired infections therapeutic Market
7.4.3. Japan Hospital acquired infections therapeutic Market
7.4.4. Australia Hospital acquired infections therapeutic Market
7.4.5. South Korea Hospital acquired infections therapeutic Market
7.4.6. Rest of Asia Pacific Hospital acquired infections therapeutic Market
7.5. Latin America Hospital acquired infections therapeutic Market Snapshot
7.5.1. Brazil Hospital acquired infections therapeutic Market
7.5.2. Mexico Hospital acquired infections therapeutic Market
7.6. Rest of The World Hospital acquired infections therapeutic Market

Chapter 8. Competitive Intelligence
8.1. Top Market Strategies
8.2. Company Profiles
8.2.1. Pfizer Inc.
8.2.1.1. Key Information
8.2.1.2. Overview
8.2.1.3. Financial (Subject to Data Availability)
8.2.1.4. Infection Summary
8.2.1.5. Recent Developments
8.2.2. MERCK & CO., Inc.
8.2.3. Bayer AG
8.2.4. GlaxoSmithKline
8.2.5. Daiichi Sankyo Company, Limited
8.2.6. AbbVie Inc.
8.2.7. Basilea Pharmaceutica AG
8.2.8. Abbott Inc.
8.2.9. F. Hoffmann-La Roche Ltd
8.2.10. Allergan Plc.
Chapter 9. Research Process
9.1. Research Process
9.1.1. Data Mining
9.1.2. Analysis
9.1.3. Market Estimation
9.1.4. Validation
9.1.5. Publishing
9.2. Research Attributes
9.3. Research Assumption